Friedrich-Schiller-Universität Jena
- Address
- Am Klinikum 1, Lobeda, 07747 Jena, Germany
Hemic and Lymphatic Diseases
The Friedrich-Schiller-Universität Jena pediatric department is advancing care for children with acute myeloid leukemia by testing innovative therapies aimed at extending event‑free survival.
- Evaluation of CPX-351 as a frontline agent for de‑novo AML
- Integration of Gemtuzumab-Ozogamicin into salvage chemotherapy for relapsed disease
- Comparison of conditioning regimens to reduce graft‑versus‑host disease and other transplant complications
- Collection of biological samples for toxicity and biomarker studies
With ten investigators and commercial partnership, the site conducts a focused program that blends academic expertise with industry support to bring new treatment options to young patients.
Neoplasms
At the same center, a dedicated trial investigates cutting‑edge regimens for multiple myeloma in newly diagnosed, transplant‑eligible patients, seeking deeper minimal residual disease responses.
- Head‑to‑head comparison of Tec-DRd versus DVRd after induction and consolidation
- Use of high‑dose melphalan followed by autologous stem cell transplantation
- Assessment of MRD negativity at a sensitivity of 10⁻⁶ as a primary efficacy endpoint
- Planning of maintenance therapy based on early response data
The multicenter, open‑label study leverages the expertise of ten investigators and benefits from commercial collaboration to accelerate therapeutic advances for this serious blood cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1GPOH gGmbH1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Friedrich-Schiller-Universität Jena
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial of Angiotensin II Versus Noradrenaline for Prevention of Cardiac Surgery-Associated Acute Kidney Injury | Universitaet Muenster | Phase I | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-01-16 | 2023-01-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.